Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 468, Issue 3, Pages 504-510Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2015.08.023
Keywords
Nanotechnology; Regulatory sciences; Nanomedicine; Biocompatibility; Quality-by-design; Manufacturing
Categories
Funding
- Fundacao para a Ciencia e a Tecnologia, Ministerio da Ciencia e da Tecnologia, Portugal [SFRH/BD/87869/2012, SFRH/BD/87150/2012, SFRH/BD/87591/2012, SFRH/BD/78480/2011, SFRH/BPD/94111/2013, PTDC/SAU-FAR/119389/2010, UTAP-ICDT/DTP-FTO/0016/2014, UID/DTP/04138/2013]
- UK Engineering & Physical Sciences Research Council (EPSRC)
- Fundação para a Ciência e a Tecnologia [UTAP-ICDT/DTP-FTO/0016/2014, SFRH/BPD/94111/2013, SFRH/BD/87869/2012, PTDC/SAU-FAR/119389/2010, SFRH/BD/87150/2012, SFRH/BD/87591/2012, SFRH/BD/78480/2011] Funding Source: FCT
Ask authors/readers for more resources
Nanomedicines have been in the forefront of pharmaceutical research in the last decades, creating new challenges for research community, industry, and regulators. There is a strong demand for the fast development of scientific and technological tools to address unmet medical needs, thus improving human health care and life quality. Tremendous advances in the biomaterials and nanotechnology fields have prompted their use as promising tools to overcome important drawbacks, mostly associated to the non-specific effects of conventional therapeutic approaches. However, the wide range of application of nanomedicines demands a profound knowledge and characterization of these complex products. Their properties need to be extensively understood to avoid unpredicted effects on patients, such as potential immune reactivity. Research policy and alliances have been bringing together scientists, regulators, industry, and, more frequently in recent years, patient representatives and patient advocacy institutions. In order to successfully enhance the development of new technologies, improved strategies for research-based corporate organizations, more integrated research tools dealing with appropriate translational requirements aiming at clinical development, and proactive regulatory policies are essential in the near future. This review focuses on the most important aspects currently recognized as key factors for the regulation of nanomedicines, discussing the efforts under development by industry and regulatory agencies to promote their translation into the market. Regulatory Science aspects driving a faster and safer development of nanomedicines will be a central issue for the next years. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available